NEI Research News

Adding omega-3 fatty acids did not improve a combination of nutritional supplements commonly recommended for treating age-related macular degeneration (AMD), a major cause of vision loss among older Americans.

Targeting cholesterol metabolism in the eye might help prevent a severe form of age-related macular degeneration (AMD), one of the most common causes of blindness in older Americans.

An international group of researchers has discovered seven new regions of the human genome—called loci-that are associated with increased risk of age-related macular degeneration (AMD), a leading cause of blindness.

Changes in how genes in the immune system function may result in age-related macular degeneration (AMD), the leading cause of visual impairment in older adults, based on preliminary research conducted by National Institutes of Health (NIH) investigators.

Researchers have developed a new prosthetic technique that can restore vision to blind mice. The approach could potentially be further developed to improve sight in blind people.

At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD).

Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD).

More than 72,000 clinical photographs illustrate age-related eye disease progression

A large genetic study of age-related macular degeneration (AMD) has identified three new genes associated with this blinding eye disease-two involved in the cholesterol pathway.

In advance of NEI director Dr. Paul A. Sieving’s recent trip to China, a poster at Tianjin Eye Hospital promoted one of his lectures.